Abstract: A 61-year-old woman with a history of pernicious anemia presented with progressive muscle weakness and dysarthria. Hypokalemic paralysis (serum potassium, 1.4 mEq/L) due to distal renal tubular acidosis (dRTA) was diagnosed. After excluding several possible causes, dRTA was considered autoimmune. However, the patient did not meet criteria for any of the autoimmune disorders classically associated with dRTA. She had very high antibody titers against parietal cells, intrinsic factor, and thyroid peroxidase (despite normal thyroid function). The patient consented to a kidney biopsy, and acidbase transporters, anion exchanger type 1 (AE1), and pendrin were undetectable by immunofluorescence. Indirect immunofluorescence detected diminished abundance of AE1-and pendrin-expressing intercalated cells in the kidney, as well as staining by the patient's serum of normal human intercalated cells and parietal cells expressing the adenosine triphosphatase hydrogen/potassium pump (H(+)/K(+)-ATPase) in normal human gastric mucosa. The dRTA likely is caused by circulating autoantibodies against intercalated cells, with possible cross-reactivity against structures containing gastric H(+)/K(+)-ATPase. This case demonstrates that in patients with dRTA without a classic autoimmune disorder, autoimmunity may still be the underlying cause. The mechanisms involved in autoantibody development and how dRTA can be caused by highly specific autoantibodies against intercalated cells have yet to be determined. The Netherlands E-mail: This case demonstrates that in patients with dRTA without a classical autoimmune disorder, autoimmunity may still be the underlying cause. The mechanisms why autoantibodies are developed and how highly specific autoantibodies against intercalated cells can cause dRTA remains to be uncovered. 
Abstract
A 61-year old woman with a previous history of pernicious anemia presented with progressive muscle weakness and dysarthria. She was diagnosed with hypokalemic paralysis (serum potassium 1.4 mEq/L) due to distal renal tubular acidosis (dRTA). After excluding several possible causes, dRTA was considered autoimmune. However, the patient did not meet the criteria for any of the autoimmune disorders classically associated with dRTA. She did have This case demonstrates that in patients with dRTA without a classical autoimmune disorder, autoimmunity may still be the underlying cause. The mechanisms why autoantibodies are developed and how highly specific autoantibodies against intercalated cells can cause dRTA remains to be uncovered.
Introduction
Distal renal tubular acidosis (dRTA, also called type I RTA) is caused by an inability of the kidney collecting duct to acidify urine (1) . The metabolic acidosis in dRTA is characterized by a normal anion gap, urinary pH > 5.3, and low ammonium excretion. dRTA is usually caused by a proton secretion defect in the intercalated cells. This proton secretion defect explains why dRTA is usually accompanied by hypokalemia, because it indirectly causes renal potassium losses and cellular shifts of potassium. dRTA may be inherited or acquired by drugs, hypercalciuria, or an underlying autoimmune disorder (2) . It has been reported in various autoimmune disorders including Sjögren's syndrome, primary biliary cirrhosis, autoimmune hepatitis, systemic lupus erythematosus, and rheumatoid arthritis (2) . How these autoimmune disorders cause dRTA is not well known. dRTA is a relatively common complication of Sjögren's syndrome, and studies have suggested the presence of autoantibodies against acid-base transporters (3) (4) (5) . Here, we report a case of dRTA associated with circulating antibodies against intercalated cells. Surprisingly, the patient did not have one of the systemic autoimmune disorders associated with dRTA, but did have multiorgan autoimmunity involving the kidney, stomach and thyroid glands. 4 
Case report
A 61-year old woman presented with progressive muscle weakness and dysarthria since one week. Her dietary habits were unremarkable and she did not have diarrhea. She used no other medication than folic acid (5 mg/day) and vitamin B12 injections because of pernicious anemia (her only medical history). She did not use H2-receptor antagonists or proton pump inhibitors. Besides paralysis (muscle strength 2/5), physical examination was normal, including examination of the thyroid. Laboratory tests at admission revealed severe hypokalemia (serum potassium 1.4 mEq/L) and non-anion gap metabolic acidosis (serum pH 7.14, bicarbonate 9 mEq/l). Hypokalemia was due to renal potassium losses (urine potassium 20 mEq/l, fractional potassium excretion 21%). The metabolic acidosis was characterized by an inappropriately high urine pH of 7.1 and a positive urine anion gap (+21 mEq/l), suggesting renal tubular acidosis (RTA). Other laboratory tests were normal, including thyroid and kidney function. She had normal sized kidneys without nephrocalcinosis. The patient was hospitalized for several weeks, initially at the intensive care unit for intravenous potassium and bicarbonate supplementation under telemetry, and is currently still treated with oral sodium bicarbonate (1500 mg daily) and potassium citrate (1800 mg daily) maintaining a normal serum potassium (4.1 mEq/L) and bicarbonate (25 mEq/L). She is currently followedup as outpatient for electrolyte and acid-base balance, and gastric and thyroid function.
After the acute phase, additional tests were performed to investigate the type and cause of
RTA. An acidification test using fludrocortisone and furosemide was performed during which she failed to reach a urine pH < 5.3 (lowest urine pH 5.5) (6). In addition, renal ammonium excretion was assessed by calculating the urine osmolal gap and found to be very low in view of the existing acidosis (11 mEq/l). These findings confirmed dRTA, although a fractional bicarbonate excretion test was not performed to formally exclude a proximal RTA. The (Figure 1) . Although residual staining for the a4 and B1 subunits was present, these co-localized in the same cells with AQP2 (Figure 1 ).
The incubation with the patient's serum on normal human kidney caused strong staining exclusively in both types of intercalated cells, whereas this was not present with control sera 6 from 5 persons (male and female, age between 30-60 years) (Figure 2) . To confirm that the staining occurred in intercalated cells, we performed double labelling with AE1 (green) and AQP2 (white, Figure 2 ). These studies showed that the patient's serum stained type A intercalated cells because of co-localization with AE1. Because the patient's serum also stained cells that were negative for AE1 and AQP2, we believe this additional staining 
Discussion
We report an unusual case of dRTA, which was clearly of autoimmune origin, but could not be linked to any systemic autoimmune disorder known to be associated with dRTA. By performing indirect immunofluorescence studies we demonstrate (1) diminished abundance of AE1 and pendrin expressing intercalated cells in the kidney of the patient, and positive staining by the patient's serum of (2) Autoantibodies against pendrin have been reported in patients with auto-immune thyroiditis and hypothyroidism (9) . Patients with mutations in pendrin present with deafness that can be accompanied by goiter and hypothyroidism; electrolyte and acid-base disorders have only been reported in these patients in the context of thiazide use or inter-current illness (9-11). 8 Also, the pathogenesis of dRTA is difficult to reconcile with dysfunctional pendrin, because this transporter is involved in renal bicarbonate secretion and sodium chloride reabsorption.
Another candidate protein would be SLC26A7, although we did not analyze this transporter in our immunolabeling studies. SLC26A7 is expressed in intercalated cells and stomach and mice lacking SLC26A7 suffer from RTA and reduced gastric acid secretion (12) . Of interest, the constellation of autoantibodies against parietal cells, intrinsic factor, and thyroid peroxidase and the occurrence of dRTA has been reported previously (13) . In this series of 113 patients, a complement fixing autoantibody was identified that reacted with the renal collecting duct.
In conclusion, this unusual case demonstrates that in patients with dRTA, autoimmune disorders must be considered that do not fit the classic disorders associated with dRTA. The diagnosis can be made by the combination of excluding these classic syndromes and the demonstration of autoantibodies against affected organs. The exact mechanisms why autoantibodies are developed and how highly specific autoantibodies against intercalated cells can cause dRTA remains to be uncovered. 
